company background image
21J logo

Jounce Therapeutics DB:21J Stock Report

Last Price

€1.67

Market Cap

€89.8m

7D

-3.5%

1Y

-64.8%

Updated

05 May, 2023

Data

Company Financials +

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

21J Stock Overview

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer.

21J fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Jounce Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Jounce Therapeutics
Historical stock prices
Current Share PriceUS$1.67
52 Week HighUS$5.13
52 Week LowUS$0.53
Beta0.75
1 Month Change-3.47%
3 Month Change61.43%
1 Year Change-64.83%
3 Year Change-62.22%
5 Year Change-88.59%
Change since IPO-89.23%

Recent News & Updates

Recent updates

Shareholder Returns

21JDE BiotechsDE Market
7D-3.5%3.3%1.6%
1Y-64.8%35.8%6.4%

Return vs Industry: 21J underperformed the German Biotechs industry which returned -5.2% over the past year.

Return vs Market: 21J underperformed the German Market which returned -3.3% over the past year.

Price Volatility

Is 21J's price volatile compared to industry and market?
21J volatility
21J Average Weekly Movement19.8%
Biotechs Industry Average Movement5.9%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 21J's share price has been volatile over the past 3 months.

Volatility Over Time: 21J's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2012141n/ahttps://jouncetx.com

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy.

Jounce Therapeutics, Inc. Fundamentals Summary

How do Jounce Therapeutics's earnings and revenue compare to its market cap?
21J fundamental statistics
Market cap€89.78m
Earnings (TTM)-€46.20m
Revenue (TTM)€74.40m

1.2x

P/S Ratio

-1.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
21J income statement (TTM)
RevenueUS$82.00m
Cost of RevenueUS$54.80m
Gross ProfitUS$27.20m
Other ExpensesUS$78.12m
Earnings-US$50.92m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.97
Gross Margin33.17%
Net Profit Margin-62.10%
Debt/Equity Ratio0%

How did 21J perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.